Khwaja Saad Haq
Research Subjects
Khwaja Saad Haq has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Teresa M. Varghese
Resident, Department of Internal Medicine, Wellstar Spalding Medical Center, Griffin, Georgia
3 shared publications - Akshita Khosla
Department of Hematology and Oncology, Louisiana State University, New Orleans, LA 70112, USA
2 shared publications - George M. Varghese
Department of Cardiovascular Medicine, Stanford University, Stanford, CA 94305, USA
2 shared publications - Gina Vaccaro
Tennessee Oncology, Nashville, Tennessee, USA
2 shared publications - Nithya Krishnakumaran
Department of Internal Medicine, Southeast Health Dothan, Dothan, AL 36301, USA
2 shared publications - Rojymon Jacob
Department of Radiation Oncology, School of Medicine, University of Mississippi Medical Center, Jackson, MS 39216, USA
2 shared publications
Latest Publications
- Open Access
- 12 September 2025
- Published by Greater Baltimore Medical Center in Journal of Community Hospital Internal Medicine Perspectives
- Vol. 15 (5) , 99-103
Unveiling the Unexpected: Duodenal Ulcer as a Manifestation of Breast Cancer Metastasis
Breast cancer typically metastasizes to the lymph nodes, lungs, bones, and liver. However, gastrointestinal (GI) involvement is exceedingly rare, particularly presenting as duodenal ulcers. Such metastases often mimic primary GI malignancies, leading to nonspecific symptoms like abdominal pain, anorexia, bleeding, and vomiting, which can delay accurate diagnosis. Early recognition through appropriate diagnostic evaluations is crucial to prevent disease progression. We report a unique case of an 86-year-old woman with multiple comorbidities who presented with multiple gastrointestinal ulcers. Further investigation revealed these lesions to be manifestations of metastatic breast cancer. This case underscores the importance of considering metastatic breast cancer in the differential diagnosis of atypical gastrointestinal presentations, even in elderly patients without a known history of malignancy.
- 12 September 2025
- Published by Greater Baltimore Medical Center in Journal of Community Hospital Internal Medicine Perspectives
- Vol. 15 (5) , 99-103
Open AccessUnveiling the Unexpected: Duodenal Ulcer as a Manifestation of Breast Cancer Metastasis
Breast cancer typically metastasizes to the lymph nodes, lungs, bones, and liver. However, gastrointestinal (GI) involvement is exceedingly rare, particularly presenting as duodenal ulcers. Such metastases often mimic primary GI malignancies, leading to nonspecific symptoms like abdominal pain, anorexia, bleeding, and vomiting, which can delay accurate diagnosis. Early recognition through appropriate diagnostic evaluations is crucial to prevent disease progression. We report a unique case of an 86-year-old woman with multiple comorbidities who presented with multiple gastrointestinal ulcers. Further investigation revealed these lesions to be manifestations of metastatic breast cancer. This case underscores the importance of considering metastatic breast cancer in the differential diagnosis of atypical gastrointestinal presentations, even in elderly patients without a known history of malignancy.
- Open Access
Impact of Race on Admission, Clinical Outcomes, and Disposition in Cholangiocarcinoma: Insights from the National Inpatient Database
Background: Cholangiocarcinoma, malignancies arising from the intrahepatic and extrahepatic bile ducts, has increased in incidence in the United States over the past few decades. The reported incidence of cholangiocarcinomas is high, particularly in specific racial groups such as Asian and Pacific Islander patients. Race also significantly impacts disparities in healthcare utilization and clinical outcomes. Our study focused on the impact of race on admission, clinical outcomes, and disposition of cholangiocarcinoma. Methods: We performed a retrospective analysis of cholangiocarcinoma-related hospital admissions, using the National Inpatient Sample for the year 2022. Patients were stratified according to race into the following groups: White, African American, Hispanic, Asian or Pacific Islander, Native American, and Other. The data analysis was performed using STATA/BE version 18.5. Univariable and multivariable logistic regression models were applied to evaluate the relationship between race and clinical and healthcare utilization outcomes. Results: In 2022, 7479 hospitalizations were recorded for cholangiocarcinoma in the United States. Among these, 65.99% were White, 13.27% Hispanic, and 10.13% African American. There was a statistically significant difference in gender distribution across racial groups (p < 0.001), with males comprising the majority in all groups. Males outnumbered females in all racial groups except among the Hispanic group. Significant racial disparities in mortality were observed, with White patients showing a mortality rate of 6.69%, compared to higher rates among African American (9.76%), Native American (8.51%), and Asian or Pacific Islander (8.09%) patients, while Hispanic (5.04%) and Other (5.88%) groups had lower rates (p < 0.001). Conclusions: The study underscores the racial disparities among cholangiocarcinoma hospitalizations, with African American, Native American, and Asian patients facing disproportionately higher mortality and poorer in-hospital outcomes compared to White patients. This analysis highlights the healthcare strategies and policy reforms to promote equitable treatment by mitigating these disparities and to improve cholangiocarcinoma outcomes.
Open AccessImpact of Race on Admission, Clinical Outcomes, and Disposition in Cholangiocarcinoma: Insights from the National Inpatient Database
Background: Cholangiocarcinoma, malignancies arising from the intrahepatic and extrahepatic bile ducts, has increased in incidence in the United States over the past few decades. The reported incidence of cholangiocarcinomas is high, particularly in specific racial groups such as Asian and Pacific Islander patients. Race also significantly impacts disparities in healthcare utilization and clinical outcomes. Our study focused on the impact of race on admission, clinical outcomes, and disposition of cholangiocarcinoma. Methods: We performed a retrospective analysis of cholangiocarcinoma-related hospital admissions, using the National Inpatient Sample for the year 2022. Patients were stratified according to race into the following groups: White, African American, Hispanic, Asian or Pacific Islander, Native American, and Other. The data analysis was performed using STATA/BE version 18.5. Univariable and multivariable logistic regression models were applied to evaluate the relationship between race and clinical and healthcare utilization outcomes. Results: In 2022, 7479 hospitalizations were recorded for cholangiocarcinoma in the United States. Among these, 65.99% were White, 13.27% Hispanic, and 10.13% African American. There was a statistically significant difference in gender distribution across racial groups (p < 0.001), with males comprising the majority in all groups. Males outnumbered females in all racial groups except among the Hispanic group. Significant racial disparities in mortality were observed, with White patients showing a mortality rate of 6.69%, compared to higher rates among African American (9.76%), Native American (8.51%), and Asian or Pacific Islander (8.09%) patients, while Hispanic (5.04%) and Other (5.88%) groups had lower rates (p < 0.001). Conclusions: The study underscores the racial disparities among cholangiocarcinoma hospitalizations, with African American, Native American, and Asian patients facing disproportionately higher mortality and poorer in-hospital outcomes compared to White patients. This analysis highlights the healthcare strategies and policy reforms to promote equitable treatment by mitigating these disparities and to improve cholangiocarcinoma outcomes.
- Open Access
- 11 June 2025
- Published by MDPI AG in Preprints.org
Impact of Race on Admission, Clinical Outcomes, and Disposition in Cholangiocarcinoma: Insights from the National Inpatient Database
Background: Cholangiocarcinoma, malignancies arising from intrahepatic and extrahepatic bile ducts, have increased in incidence in the United States over the past few decades. The reported incidence of cholangiocarcinomas is high, particularly in certain racial groups such as Asian and Pacific Islanders. Race also significantly impacts disparities in healthcare utilization and clinical outcomes. Our study focused on the impact of race on admission, clinical outcomes, and disposition of cholangiocarcinoma. Methods: We performed a retrospective analysis of cholangiocarcinoma-related hospital admissions, using the National Inpatient Sample for the year 2022. Patients were stratified according to race into the following groups: White, African Americans, Hispanics, Asian or Pacific Islanders, Native Americans, and Others. The data analysis was performed using STATA/BE version 18.5. Univariate and Multivariable logistic regression models were applied to evaluate the relationship between race and clinical and healthcare utilization outcomes. Results: In 2022, 7479 hospitalizations were recorded for cholangiocarcinoma in the United States. Among these, 65.99% were Whites, 13.27% Hispanics, and 10.13% African-Americans. There was a statistically significant difference in gender distribution across racial groups (p< 0.001), with males comprising the majority in all groups. Males outnumbered females in all racial groups except among Hispanics. Significant racial disparities in mortality were observed, with White patients showing a mortality rate of 6.69%, compared to higher rates among African-American (9.76%), Native American (8.51%), and Asian or Pacific Islander (8.09%) patients, while Hispanic (5.04%) and Other (5.88%) groups had lower rates (p< 0.001). Conclusions: The study underscores the racial disparities among cholangiocarcinoma hospitalizations, with African Americans, Native Americans, and Asian patients facing disproportionately higher mortality and poorer in-hospital outcomes compared to White patients. This analysis highlights the healthcare strategies and policy reforms to promote equitable treatment by mitigating these disparities and to improve cholangiocarcinoma outcomes.
- 11 June 2025
- Published by MDPI AG in Preprints.org
Open AccessImpact of Race on Admission, Clinical Outcomes, and Disposition in Cholangiocarcinoma: Insights from the National Inpatient Database
Background: Cholangiocarcinoma, malignancies arising from intrahepatic and extrahepatic bile ducts, have increased in incidence in the United States over the past few decades. The reported incidence of cholangiocarcinomas is high, particularly in certain racial groups such as Asian and Pacific Islanders. Race also significantly impacts disparities in healthcare utilization and clinical outcomes. Our study focused on the impact of race on admission, clinical outcomes, and disposition of cholangiocarcinoma. Methods: We performed a retrospective analysis of cholangiocarcinoma-related hospital admissions, using the National Inpatient Sample for the year 2022. Patients were stratified according to race into the following groups: White, African Americans, Hispanics, Asian or Pacific Islanders, Native Americans, and Others. The data analysis was performed using STATA/BE version 18.5. Univariate and Multivariable logistic regression models were applied to evaluate the relationship between race and clinical and healthcare utilization outcomes. Results: In 2022, 7479 hospitalizations were recorded for cholangiocarcinoma in the United States. Among these, 65.99% were Whites, 13.27% Hispanics, and 10.13% African-Americans. There was a statistically significant difference in gender distribution across racial groups (p< 0.001), with males comprising the majority in all groups. Males outnumbered females in all racial groups except among Hispanics. Significant racial disparities in mortality were observed, with White patients showing a mortality rate of 6.69%, compared to higher rates among African-American (9.76%), Native American (8.51%), and Asian or Pacific Islander (8.09%) patients, while Hispanic (5.04%) and Other (5.88%) groups had lower rates (p< 0.001). Conclusions: The study underscores the racial disparities among cholangiocarcinoma hospitalizations, with African Americans, Native Americans, and Asian patients facing disproportionately higher mortality and poorer in-hospital outcomes compared to White patients. This analysis highlights the healthcare strategies and policy reforms to promote equitable treatment by mitigating these disparities and to improve cholangiocarcinoma outcomes.